US President Donald Trump on Thursday announced deals to lower the cost of weight loss drugs Wegovy and Zepbound, a move that could vastly expand access to the blockbuster medications.
The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly $1,350 to $149 per month. The US health secretary estimated that because of the lower costs, Americans could lose a collective 125 million pounds by next November.
The benefits of GLP-1 drugs go beyond weight loss: Experts say they reduce spending on fast food and processed snacks, and studies have shown they can improve heart health.
